{
  "id": 10428232,
  "title": "Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation",
  "url": "https://urgent.news/2026/09/28/psyence-biomed-announces-exclusive-u-s-ibogaine-licence-for-texas",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T11:04:04.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/psyence-biomed-announces-exclusive-u-s-ibogaine-licence-for-texas-ibogaine-research-corporation"
  },
  "original_language": "en",
  "account": null,
  "summary": "Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}